Opens a gap on competitors: Pfizer will today apply to the...

The CEO of the American Pharmaceutical Company announced the submission of the emergency permit application for the vaccine • He once again confirmed that there is an agreement for the supply of vaccines to Israel • “Once the green light is given – ready to distribute the vaccine within hours”


| Posted 20/11/20 14:52

Photography: shutterstock

Pfizer CEO Albert Burla announced today (Friday) that the company will file an emergency clearance request from the U.S. Food and Drug Administration. A green light, as soon as it is received – we are ready to start spreading the vaccine within hours. “

For more updates and to send your stories – visit the news page

“We hope for a change of government in parts of the U.S. so that we can move forward properly,” Burla continued, “We plan to monitor at least two-year-old vaccinators to understand how long the vaccine lasts. It is possible to inject booster injections that will raise the level of antibodies (one more injection each time). “Burla once again confirmed that there is a signed agreement with Israel and other countries to supply vaccines if they are approved. .

Albert Burla (Photo: AP PhotoPablo Martinez Monsivais)
Pfizer CEO Albert Burla | Photo: AP PhotoPablo Martinez Monsivais

After Pfizer passed intermediate results from the experiment that showed that Its vaccine effectiveness stands at 90%, the drug giant announced yesterday that the third phase of the trial has been completed, and the updated results show that the vaccine is 95% effective.

The company added in the official announcement they published about the completion of the trial that 95% of the efficacy percentages are correct starting from 28 days from the day the participant received the first dose of the vaccine out of two. The second dose was given 7 days after the first dose. The results of the experiment also showed that the efficiency index was consistent regardless of race, gender, age and demographics. The effectiveness of the vaccine in adults aged 65 and over, for example, is 94%.

Vaccine bottles (Photo: shutterstock)
Photo: shutterstock

According to the company, there is no safety concern about the vaccine, and they have met the threshold set by the FDA and EUA. An overwhelming majority of the more than 43,000 participants in the experiment did not experience significant side effects. 3.7% of them experienced fatigue, and only 2% suffered from headaches.

Pfizer added that by the end of 2020 they will be able to produce 50 million doses of vaccine, and by the end of 2021 they will reach 1.3 billion doses. The vaccines are expected to be manufactured and distributed at the company’s production centers in the US, Belgium and Germany.

These were the details of the news Opens a gap on competitors: Pfizer will today apply to the... for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

NEXT Abu Dhabi fund, CVC said to be among suitors for $1bn NMC hospital business